The orexin system is your brain's primary wakefulness engine. Two neuropeptides — orexin A and orexin B — are released by a small cluster of hypothalamic neurons and broadcast across the brainstem to maintain alert wakefulness. They bind two receptors: HCRTR1 (orexin receptor 1) and HCRTR2 (orexin receptor 2)¹¹ HCRTR2 (orexin receptor 2)
the protein encoded by this gene, expressed in histaminergic, noradrenergic, and serotonergic nuclei that sustain wakefulness throughout the day. HCRTR2 is also the direct molecular target of the FDA-approved sleep medications suvorexant (Belsomra) and lemborexant (Dayvigo), which work by blocking it to allow sleep onset. This makes rs2653349 unusual: it sits within the drug target itself, meaning your genotype here directly describes the protein that sleep medications act on.

rs2653349 causes a missense change at codon 308 of HCRTR2 (NM_001526.5:c.922A>G, p.Ile308Val). The common G allele encodes valine (Val308), which is the functional wild-type at this position. The minor A allele encodes isoleucine (Ile308). Globally, about 81% of people carry two G alleles (Val308Val homozygous) and only about 4% carry two A alleles (Ile308Ile homozygous). The A allele is more common in European populations (~21%) than in East Asian ones (~5%).

The Mechanism

Codon 308 in HCRTR2 sits within the transmembrane domain of the receptor protein — the region that spans the cell membrane and is central to ligand binding and signal transduction. Substituting valine for isoleucine at this position alters the hydrophobic packing of the transmembrane helix, and homologous substitutions in canine HCRTR2 disrupt receptor signalling and produce narcolepsy²² homologous substitutions in canine HCRTR2 disrupt receptor signalling and produce narcolepsy
the narcoleptic Doberman mutation in HCRTR2 is a reference model for orexin receptor dysfunction. The human Ile308 (A allele) variant is thought to modestly reduce receptor signalling efficiency, attenuating the wake-promoting output of the orexin system.

The consequence is a quantitative shift toward increased sleepiness and daytime napping tendency rather than the catastrophic narcolepsy seen with complete receptor loss. The effect is additive: each A allele adds a small decrement to orexin-driven wakefulness.

The Evidence

The primary evidence comes from Dashti et al. 2021³³ Dashti et al. 2021
Genetic determinants of daytime napping and effects on cardiometabolic health. Nature Communications, a genome-wide association study of daytime napping in 993,966 individuals (UK Biobank discovery, 23andMe replication). The A allele at rs2653349 reached p = 6×10⁻⁵² for more frequent napping — among the most significant of 123 identified loci. Colocalization analysis confirmed that the same variant drives associations across napping frequency, evening chronotype, and reduced ease of awakening, identifying rs2653349 as a shared causal missense variant influencing multiple dimensions of sleep-wake regulation.

Jones et al. 2019⁴⁴ Jones et al. 2019
Genome-wide association analyses of chronotype in 697,828 individuals. Nature Communications independently found the A allele associated with evening chronotype (OR 1.068, p = 3×10⁻⁴⁸), consistent with reduced orexin morning wake drive. Mendelian randomisation in that dataset demonstrated that morning preference causally reduces schizophrenia risk (OR 0.89) and improves subjective well-being — consequences that flow indirectly from orexin receptor function.

A Japanese replication study (Miyagawa et al. 2022⁵⁵ Miyagawa et al. 2022
Journal of Human Genetics, n = 14,329) found nominally significant association between Ile308Val and daytime sleepiness (p = 0.044), providing cross-ancestry corroboration.

On the pharmacogenomics side, Firouzabadi et al. 2020⁶⁶ Firouzabadi et al. 2020
Neuropsychiatric Disease and Treatment found that GG homozygotes (Val308Val) — the common, wake-biased genotype — had 2.5-fold higher odds of developing insomnia during sertraline treatment for depression (OR 2.5, 95% CI 1.1–5.7, n = 96 MDD patients). This is a small study requiring replication, but the direction is biologically coherent: a more active orexin receptor may resist the sleep-disrupting side effects of serotonin reuptake inhibitors via arousal-system feedback.

Nishizawa et al. 2015⁷⁷ Nishizawa et al. 2015
Molecular Brain identified rs2653349 as the top hit in a GWAS of Fagerström nicotine dependence scores in a Japanese cohort, with the A allele associated with higher dependence (p = 0.0006). Orexin signalling is involved in addiction circuits, particularly craving and reward salience — suggesting that reduced HCRTR2 activity from Ile308 may modulate addictive behaviour alongside its sleep effects.

Practical Actions

For A allele carriers: a slightly reduced orexin wake drive means afternoon sleepiness and napping are partly constitutional, not just a lifestyle choice. Light-anchoring strategies and consistent sleep timing are especially important to prevent accumulating sleep pressure from fragmenting into chronic napping patterns.

For GG individuals: the stronger Val308 orexin signal maintains robust wakefulness but the Firouzabadi data suggests monitoring for sleep disruption if prescribed serotonergic antidepressants. GG individuals also need to know that suvorexant and lemborexant — which block Val308 receptors that are operating at full efficiency — may require careful dose titration.

Interactions

rs2653349 is one of three characterised functional variants in HCRTR2 in the GeneOps database. rs35833281 is an intronic chronotype tag SNP; rs1154155 is separately studied in narcolepsy and cluster headache literature. These variants may tag independent effects at the same locus or be in partial LD with rs2653349.

The orexin system interacts with the dopamine reward circuit (relevant to the nicotine dependence finding), with histaminergic arousal centres (where HCRTR2 drives the histamine wake signal), and with serotonergic nuclei (explaining the sertraline-insomnia pharmacogenomics finding). Variants in histamine pathway genes (e.g., HDC, HRH1) could compound the HCRTR2 sleepiness effect.

SLC22A2 encodes organic cation transporter 2 (OCT2), the dominant transporter on the basolateral membrane of kidney proximal tubule cells. OCT2 is responsible for the first and rate-limiting step in renal secretion of metformin: uptake from the bloodstream into tubular epithelial cells. Without efficient OCT2 transport, metformin accumulates in plasma at higher concentrations than expected — which may enhance glucose lowering but also risks lactic acidosis in susceptible patients. The same transporter also mediates uptake of cisplatin and oxaliplatin into renal and cochlear cells, making OCT2 genotype a determinant of platinum chemotherapy toxicity.

The rs316019 variant (c.808G>T in coding notation, p.Ser270Ala) substitutes alanine for serine at position 270 of the OCT2 protein. This position sits in a substrate-binding domain, and structural modeling¹¹ structural modeling
Sajib et al. 2018 showed substrates fit better to the Ser270 form than the Ala270 form demonstrates that the Ala270 variant creates a suboptimal binding conformation for its substrates, reducing transport efficiency.

OCT2 operates as an electrogenic uniporter driven by the inside-negative membrane potential of proximal tubule cells. At the molecular level, Ser270 participates in substrate coordination within the transmembrane binding pocket²² transmembrane binding pocket
OCT2 has 12 transmembrane domains; position 270 is in the intracellular loop region near TM5-6, involved in substrate translocation. The Ala270 substitution (a non-polar, smaller side chain replacing a polar hydroxyl group) reduces substrate affinity and transport velocity, resulting in approximately 16% lower metformin renal secretory clearance in carriers.

The same OCT2 reduction in function has a dual consequence for platinum drugs: in cochlear hair cells and renal tubular cells, cisplatin entry depends on OCT2. Carriers with reduced OCT2 activity take up less cisplatin into these sensitive tissues, partially protecting against hearing loss and kidney injury.

Metformin pharmacokinetics:

A clinical pharmacokinetic study of healthy subjects demonstrated that rs316019 carriers had significantly lower metformin renal clearance compared to non-carriers (586 ± 161 vs 699 ± 291 mL/min, p=0.048), with correspondingly higher Cmax and AUC. The same pattern was reported in a Korean healthy volunteer study, where subjects with the c.808G>T variant showed reduced metformin Cmax and altered AUC compared to wild-type GG carriers .

A mechanistic study found that SLC22A2 c.596C>T, c.602C>T, and c.808G>T all showed significant differences in metformin pharmacokinetics³³ all showed significant differences in metformin pharmacokinetics
Song et al. Clin Pharmacol Ther 2008 compared to the reference genotype, with decreased transporter function resulting in reduced renal metformin clearance and consequently increased plasma concentrations.

A critical caveat comes from a controlled interaction study: when rs316019 was analyzed in isolation without co-consideration of MATE1 variants, the effect on metformin clearance was not statistically significant. Only when examining the combined genotype with MATE1 rs2289669 did the OCT2 variant produce significant changes in renal clearance (28.1 to 44.8 L/h, p=0.004)⁴⁴ renal clearance (28.1 to 44.8 L/h, p=0.004)
Christensen et al. Pharmacogenet Genomics 2013, n=50 healthy Caucasians. This gene-gene interaction with the efflux transporter is the primary context in which rs316019 becomes clinically relevant.

Cisplatin toxicity:

In 130 patients (64 pediatric, 66 adult) receiving cisplatin-based chemotherapy, the rs316019 GT heterozygous genotype conferred striking protection against cisplatin-induced ototoxicity⁵⁵ cisplatin-induced ototoxicity
Lanvers-Kaminsky et al. Pharmacogenomics 2015 with OR 0.12 (95% CI 0.02–0.67, p=0.009) — an 88% relative risk reduction for hearing damage versus GG homozygotes.

In a Chinese cohort of 123 cancer patients, the GT/TT genotype was also associated with smaller increases in cystatin C (a sensitive marker of kidney damage) following cisplatin treatment compared to GG carriers (P=0.043). Paradoxically, a separate study reported that rs316019 carriers had higher baseline urinary KIM-1 (kidney injury molecule-1) levels, and elevated KIM-1 at day 3 and day 10 post-cisplatin, suggesting that the relationship between OCT2 genotype and cisplatin nephrotoxicity is more complex than simple protection.

For metformin users: The standalone pharmacokinetic effect of rs316019 is modest (16% clearance reduction) and is amplified substantially when combined with MATE1 variants. Heterozygotes and homozygotes may accumulate slightly higher plasma metformin levels, which becomes clinically relevant mainly in situations of renal impairment, dehydration, iodinated contrast administration, or concurrent use of OCT2 inhibitors such as cimetidine, ranitidine, or trimethoprim.

For oncology patients: If you carry the rs316019 A allele and are scheduled to receive cisplatin-based chemotherapy, this information may be valuable for your oncologist. The reduced cisplatin uptake into cochlear hair cells appears to lower ototoxicity risk, which is particularly relevant in pediatric oncology where hearing preservation is critical for development. This finding should be weighed against the potential for altered cisplatin efficacy.

The most important interaction for metformin response is between OCT2 rs316019 and MATE1 rs2289669. OCT2 mediates metformin uptake from blood into proximal tubule cells (influx), while MATE1 (SLC47A1) mediates the final secretion step from tubular cell into urine (efflux). Christensen et al. demonstrated that the combined genotype at these two loci — not either variant alone — is the primary determinant of renal metformin clearance. A compound action covering both rs316019 and rs2289669 would reflect this documented biology.

OCT2 also interacts with OCT1 (SLC22A1, rs622342) in determining overall metformin handling: OCT1 controls hepatic uptake (determining the glucose-lowering effect), while OCT2 controls renal secretion (determining drug clearance and plasma levels). Combined OCT1+OCT2 poor transporter status would create a complex pharmacokinetic picture: reduced hepatic efficacy and reduced renal clearance simultaneously.

When you try to lose weight, two hormones drive most of the work: insulin directs your cells to take up glucose, and leptin tells your hypothalamus to suppress appetite and ramp up energy expenditure. Both signals are time-limited — an enzyme called PTP1B, encoded by the PTPN1 gene on chromosome 20, dephosphorylates and inactivates their receptors, ending each signaling pulse. When PTP1B is more active or more abundant, those windows close faster, and both insulin efficiency and leptin responsiveness decline.

rs3787348 sits within an intron of PTPN1, inside the same ~100-kb haplotype block¹¹ ~100-kb haplotype block
A region of DNA inherited together because it rarely recombines; all associated PTPN1 variants fall within this block, identified by Bento et al. 2004 that harbors every PTPN1 variant linked to insulin resistance and type 2 diabetes in human genetics studies. The T allele tags the risk haplotype. The signal at rs3787348 is intronic — the variant itself does not change the PTP1B protein, but it marks a regulatory haplotype associated with higher PTPN1 transcript levels through a functional 3'-UTR insertion²² 3'-UTR insertion
A variant in the untranslated region at the end of the PTPN1 mRNA that stabilizes the transcript, increasing the amount of PTP1B protein produced in skeletal muscle in the same block.

The Mechanism

PTP1B terminates insulin signaling by removing phosphate groups from activated tyrosine residues on the insulin receptor kinase domain — the same step that initiates glucose uptake in muscle and fat cells. In the hypothalamus, PTP1B dephosphorylates JAK2³³ JAK2
Janus kinase 2, the first intracellular enzyme activated when leptin binds its receptor in the hypothalamus; its inactivation by PTP1B blunts leptin's appetite-suppressing and thermogenic signals, terminating the leptin signal. When the PTPN1 risk haplotype drives higher PTP1B expression, both dephosphorylation events happen faster and more completely — producing a state of simultaneously reduced insulin sensitivity and reduced leptin sensitivity. In whole-body PTP1B knockout mice this dual pathway effect manifests as insulin hypersensitivity and resistance to diet-induced obesity; in the context of the human risk haplotype, the converse obtains.

The additive dose-response of rs3787348 — with each copy of the T allele increasing the weight-loss blunting effect — is consistent with a codominant regulatory mechanism where the risk haplotype progressively elevates PTPN1 expression.

The Evidence

The primary functional evidence for rs3787348 specifically comes from Yamakage et al. 2021⁴⁴ Yamakage et al. 2021
Yamakage H et al. Association of protein tyrosine phosphatase 1B gene polymorphism with the effects of weight reduction therapy on bodyweight and glycolipid profiles in obese patients. J Diabetes Investig, 2021, a prospective cohort study of 447 obese Japanese patients who underwent a standardised 3-month lifestyle intervention (caloric restriction to 25 kcal/kg ideal body weight, 60% carbohydrate, more than 30 minutes of moderate exercise at least 3 days per week). Genotyping rs3787348 and a second PTPN1 tag SNP (rs6067484) revealed a striking genotype-dependent gradient in weight loss outcomes: GG homozygotes lost 5.1 ± 0.5 kg on average, GT heterozygotes lost 4.1 ± 0.2 kg, and TT homozygotes lost only 3.1 ± 0.3 kg (p = 0.001). BMI reductions followed the same pattern (−1.9, −1.5, and −1.2 kg/m², respectively; p = 0.001), as did waist circumference reductions and leptin reductions during therapy. The T allele was also associated with higher baseline BMI (p = 0.041), consistent with a chronic dampening of leptin-mediated energy balance.

The broader haplotype context was established by Bento et al. 2004⁵⁵ Bento et al. 2004
Bento JL et al. Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2 diabetes. Diabetes, 2004, who identified the 100-kb LD block and estimated an odds ratio of approximately 1.3 for type 2 diabetes from the risk haplotype — with a population-attributable risk of 17-20%, among the highest for any noncoding T2D locus. Florez et al. 2004⁶⁶ Florez et al. 2004
Florez JC et al. Association of PTPN1 polymorphisms with measures of glucose homeostasis in Hispanic Americans: the IRAS Family Study. Diabetes, 2004 confirmed these findings in 811 Hispanic Americans, with all 20 common haplotype-block SNPs associating with the insulin sensitivity index and fasting glucose.

Notably, a 2025 meta-analysis of 75,595 individuals across multiple cohorts found no statistically significant association between rs3787348 and type 2 diabetes risk (OR = 1.02, 95% CI 0.95–1.08), confirming that the T2D risk at this locus is likely distributed across multiple correlated variants in the LD block rather than residing uniquely at rs3787348 itself. The clearest individual signal for this SNP is in treatment response, not incident T2D.

Practical Actions

The weight-loss blunting effect of the T allele has a direct clinical implication: carriers who invest in a calorie-restriction and exercise program should expect a more modest BMI response than the population average, not a failure of adherence. Concretely, at the TT genotype, a 3-month structured program produces roughly 40% less weight loss than the GG reference — a difference that often goes undiagnosed and leads to premature discontinuation of a working intervention.

Exercise is specifically valuable because moderate-intensity aerobic activity transiently reduces PTP1B protein activity in skeletal muscle, extending the effective insulin signaling window — a direct pharmacological bypass of the PTP1B-mediated brake. Higher exercise volumes and more frequent sessions maintain this suppression for more hours per week. Monitoring leptin and adiponectin levels during a weight loss program provides objective data on whether the hormonal response to weight loss is proportional — T allele carriers may see blunted leptin reductions even as weight falls.

Interactions

The most relevant interaction is with rs6067484, the closely linked PTPN1 tag SNP that co-tags the same 100-kb risk haplotype. In the Yamakage 2021 study, rs6067484 showed only nominal association with waist circumference response, while rs3787348 showed the stronger and broader effect on BMI, bodyweight, and leptin reduction. Carriers of the T allele at rs3787348 who also carry the G allele at rs6067484 represent the densest haplotype coverage of the PTPN1 risk block.

PTP1B also interacts with the leptin receptor (LEPR) pathway — animal studies demonstrate that PTP1B × leptin receptor interactions compound the degree of hypothalamic leptin resistance. Carriers of rs3787348 T allele and risk variants in LEPR may experience additive impairment of energy balance regulation.

Between the two type-II classical cadherin genes CDH9 and CDH10 on chromosome 5p14.1 lies one of the most replicated common variant associations with autism spectrum disorder (ASD). The rs4307059 C allele was the lead signal from the first genome-wide significant common variant discovery in autism¹¹ first genome-wide significant common variant discovery in autism
Wang K et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature, 2009, a landmark study that fundamentally changed how the genetics of social cognition was understood.

CDH9 and CDH10 encode [type-II neuronal cadherins | Classical cadherins are calcium-dependent cell-adhesion proteins that mediate cell-cell recognition; type-II cadherins are brain-enriched and guide synapse specificity during circuit assembly] — a family of calcium-dependent cell-adhesion molecules critical for establishing precise synaptic connections during brain development. Unlike structural cadherins in epithelial tissue, CDH9 and CDH10 are expressed in specific neuronal populations and act as molecular "zip codes" that help matching pre- and post-synaptic neurons recognize one another during circuit formation.

The Mechanism

The rs4307059 variant sits in an intergenic region between CDH9 and CDH10 and is classified as intronic within the uncharacterized locus LOC124901176. It does not alter the amino acid sequence of either cadherin. Instead, it is believed to function as a [regulatory element | A DNA sequence that controls when, where, and how much a nearby gene is expressed — can be an enhancer, silencer, or insulator] influencing the expression levels or timing of CDH10 or CDH9 during fetal brain development.

Wang et al. (2009) showed by [in situ hybridization | A technique that detects the location of specific mRNA molecules in tissue sections, showing where a gene is active] that CDH10 is expressed with marked enrichment in the orbitofrontal cortex and frontal cortex — precisely the regions implicated in social cognition, executive function, and Theory of Mind. Crucially, the study found that SNP genotypes at rs4307059 were not associated with CDH9 or CDH10 transcript levels in cortical brain tissue from adults, pointing toward a developmental window during fetal synaptogenesis when the regulatory effect is most relevant.

Neuronal cadherin-mediated adhesion is also central to [GABAergic interneuron | Inhibitory neurons that use GABA as their neurotransmitter; they fine-tune excitatory activity and are essential for cortical circuit balance] circuit assembly. Type-II cadherins guide the laminar positioning of interneuron populations during cortical development, and disruptions in this process have been mechanistically linked to both the excitatory- inhibitory imbalance observed in ASD and to sleep architecture disturbances — since GABAergic circuits regulate both social behavior and NREM sleep oscillations.

The Evidence

The original Wang et al. (2009) study²² original Wang et al. (2009) study
Wang K et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature, 2009 examined 780 families (3,101 subjects) as a discovery cohort and independently replicated the signal in 1,204 affected individuals and 6,491 controls — all of European ancestry. Six SNPs between CDH10 and CDH9 reached genome-wide significance, with rs4307059 as the lead signal (OR = 1.19, p = 3.4×10⁻⁸). The combined analysis across all cohorts reached p = 2.1×10⁻¹⁰, making this the first genome-wide-significant common variant finding in autism research.

The effect size is modest (OR = 1.19 per C allele), consistent with the highly polygenic architecture of ASD. The C allele is common in European populations (~38%) and rarer in African populations (~7%), which affects population-specific risk estimates substantially.

A large Swedish twin study Jonsson et al. (2014)³³ Jonsson et al. (2014)
Jonsson L et al. Association study between autistic-like traits and polymorphisms in the autism candidate regions RELN, CNTNAP2, SHANK3, and CDH9/10. Mol Autism, 2014 of 12,319 children did not replicate the association with autistic-like traits in the general population. This non-replication is informative: it suggests that rs4307059's effect is specific to the clinical ASD phenotype (or its more severe end) rather than continuously distributed social traits across the population. This is a common finding for neuropsychiatric common variants — they reach significance in case- control ASD studies but show no measurable association with trait variation in unselected samples.

Practical Context

Sleep disturbances affect 40–80% of individuals with ASD, representing one of the most consistent and impactful co-occurring features. The biological link between CDH9/CDH10 circuit assembly and sleep is indirect but mechanistically grounded: frontal and orbitofrontal cortical circuits, where CDH10 is most enriched, regulate the GABAergic interneuron networks that orchestrate NREM sleep spindles and slow waves. Disrupted cadherin-mediated synaptogenesis in these circuits may produce both the social-cognitive and sleep phenotypes observed in ASD.

The C allele at rs4307059 confers a modest increase in ASD risk, and among people diagnosed with ASD, proactive management of sleep is the most actionable implication. Sleep disturbances amplify sensory sensitivity, reduce frustration tolerance, and worsen executive function — all areas directly affected by the frontal circuit dysfunction associated with this locus.

Interactions

The 5p14.1 locus at rs4307059 was originally positioned alongside CNTNAP2 (rs7794745) and SHANK3 variants as part of the neuronal cell-adhesion and synaptic scaffolding network implicated in ASD. While CNTNAP2 (chr7q35) and CDH9/CDH10 (chr5p14.1) are on different chromosomes and act through distinct synaptic mechanisms, they converge on the same developmental outcome: assembly of cortical inhibitory circuits during a critical window of fetal neurogenesis. Individuals carrying risk alleles at both loci may have compounding disruption to this circuit assembly process, though published interaction studies specifically testing rs4307059 × CNTNAP2 combinations are lacking.

T-cadherin (also called H-cadherin) is encoded by the CDH13 gene and is one of the body's most abundant adipokine receptors. Unlike other cadherin proteins, T-cadherin lacks the intracellular signalling domain and is anchored to the cell surface by a GPI anchor¹¹ GPI anchor
Glycosylphosphatidylinositol: a lipid anchor that tethers proteins to the outer leaflet of the plasma membrane, common in signalling receptors on vascular cells. On vascular endothelial cells and smooth muscle, T-cadherin acts as the primary binding receptor for high-molecular weight (HMW) adiponectin — the cardioprotective form of the most abundant circulating adipokine. The rs4783244 variant in intron 1 of CDH13 is among the strongest GWAS signals ever identified for circulating adiponectin levels, yet its health consequences are the opposite of what you might expect from the adiponectin number alone.

The Mechanism

rs4783244 sits in the first intron of CDH13 and influences the gene's transcriptional activity. The 2021 functional haplotype study by Er et al.²² 2021 functional haplotype study by Er et al.
Er et al. Genome-Wide Association Study on Adiponectin-Mediated Suppression of HDL-C Levels in Taiwanese Individuals Identifies Functional Haplotypes in CDH13. Genes, 2021 showed that the GG haplotype (tagged by the G allele at rs4783244) increased CDH13 enhancer activity by approximately 80%, while the TT haplotype reduced it by about 28%. This means the G allele drives higher CDH13/T-cadherin expression on vascular cells.

The paradox emerges here: higher T-cadherin expression means more binding capacity for HMW adiponectin — which sequesters it at the cell surface and lowers the concentration of freely circulating adiponectin. The G allele therefore produces higher circulating adiponectin as a compensatory response³³ higher circulating adiponectin as a compensatory response
Elevated adiponectin in G-allele carriers reflects an adiponectin-resistant state where more adiponectin is produced to overcome reduced signalling efficiency at the receptor level, similar to how elevated insulin can indicate insulin resistance rather than metabolic health. The T allele reduces CDH13 expression, resulting in lower circulating adiponectin but more efficient transduction of each adiponectin molecule that does bind.

The Evidence

The CDH13 locus was first identified as a top GWAS hit for adiponectin in a 2011 Taiwanese cohort study⁴⁴ 2011 Taiwanese cohort study
Chung et al. A genome-wide association study reveals a quantitative trait locus of adiponectin on CDH13 that predicts cardiometabolic outcomes. Diabetes, 2011. The rs4783244 SNP in intron 1 was the lead signal (p=7.57×10⁻⁹). Crucially, T allele carriers in that study had lower adiponectin but better cardiometabolic outcomes: metabolic syndrome OR=1.42 per G allele, T2D OR=3.25 for men with GG, and ischemic stroke OR=2.13 per G allele.

The largest effect-size estimate comes from a 2013 meta-analysis of 7,334 East Asians by Gao et al.⁵⁵ 2013 meta-analysis of 7,334 East Asians by Gao et al.
Gao et al. Genetic variation in CDH13 is associated with lower plasma adiponectin levels but greater adiponectin sensitivity in East Asian populations. Diabetes, 2013. Each T allele reduced total adiponectin by β=−0.34 (p=2×10⁻⁷⁰) and HMW adiponectin by β=−0.40 (p=1×10⁻¹¹⁷), explaining 6.5% of HMW adiponectin variance. But after adjusting for adiponectin levels, the T allele was associated with lower BMI (β=−0.15), reduced insulin resistance (β=−0.16), lower triglycerides (β=−0.16), and higher HDL cholesterol (β=0.16) — a uniformly better metabolic profile.

Long-term outcome data from the J-SHIPP study (Uetani et al. 2014)⁶⁶ J-SHIPP study (Uetani et al. 2014)
Uetani et al. CDH13 genotype-dependent association of high-molecular weight adiponectin with all-cause mortality: the J-SHIPP study. Diabetes Care, 2014 followed 2,020 Japanese subjects for a mean of 6.5 years. All-cause mortality risk increased linearly with the number of G alleles (p=0.023 for genotype interaction), and the HMW adiponectin-to-mortality relationship showed a hazard ratio of 1.92 (p=0.006) — a finding consistent with elevated adiponectin being a marker of metabolic stress rather than protection in this gene context.

A Japanese study of 945 subjects by Kitamoto et al. 2016⁷⁷ Japanese study of 945 subjects by Kitamoto et al. 2016
Kitamoto et al. CDH13 Polymorphisms are Associated with Adiponectin Levels and Metabolic Syndrome Traits Independently of Visceral Fat Mass. J Atheroscler Thromb, 2016 confirmed that the G allele association with higher adiponectin persisted even after adjusting for visceral fat — ruling out obesity as a confounder and supporting the intrinsic adiponectin-resistance model.

Practical Actions

For carriers of one or two copies of the G allele (GG or GT), the key insight is that a standard serum adiponectin measurement may appear reassuring (adiponectin looks high) while masking a functionally impaired adiponectin-signalling state. Conventional adiponectin thresholds for cardiovascular risk stratification were developed without CDH13 genotyping. In G allele carriers, it is more informative to track direct metabolic biomarkers — fasting insulin, HOMA-IR, triglycerides, and HDL — than to rely on adiponectin levels as a proxy for cardiometabolic health.

For TT homozygotes, lower circulating adiponectin is expected and does not indicate a problem; the signal-per-molecule is more efficient. Standard metabolic biomarkers apply without the CDH13-specific caveat.

Interactions

The CDH13 locus contains several variants in partial LD with rs4783244. rs12051272 (also intron 1) showed the strongest single-SNP association in the Japanese population (p=9.5×10⁻²⁰ for HMW adiponectin in Morisaki et al. 2012). rs3865188 and rs12922394 are in the same haplotype block and were examined in the Kitamoto 2016 and COPD studies. These four variants together define the CDH13 risk haplotype; a user carrying the G allele at rs4783244 likely carries the risk-tagged alleles at the others.

There is a documented interaction between CDH13 rs7193788 and type 2 diabetes: in the Chen et al. 2017 Chinese stroke study, diabetic GA/AA carriers at rs7193788 faced OR=2.64 for ischemic stroke — suggesting CDH13-mediated adiponectin signalling interacts with glycaemic status to modulate vascular risk.

The LRP8 gene¹¹ LRP8 gene
encodes ApoER2, apolipoprotein E receptor 2, a member of the LDL receptor superfamily that binds apolipoprotein E-enriched lipoproteins and mediates their endocytosis into cells. While LRP8 is best known for its role in neuronal Reelin signaling, it is also prominently expressed in adipocytes and macrophages, where it participates in apoE-directed lipid trafficking — making variants in this gene of potential relevance to fat storage and cardiovascular risk.

The Trp466Cys variant (rs5181) replaces a conserved tryptophan residue in the ligand-binding domain of LRP8 with a cysteine. Tryptophan residues in LDL receptor family ligand-binding repeats typically participate in the hydrophobic core of beta-hairpin structures²² hydrophobic core of beta-hairpin structures
The beta-hairpin fold positions the acidic residues that coordinate calcium and create the ligand-docking surface, and their substitution with cysteine introduces a free thiol group that can disrupt disulfide bonding patterns, potentially altering receptor conformation and ligand-binding affinity.

Note: Population frequency data for this variant are not available in current major databases (gnomAD, 1000 Genomes), indicating it is rare or population-restricted. The clinical interpretation below is based on the known biology of the LRP8 ligand-binding domain and the functional consequences documented for other LRP8 missense variants. Direct evidence for the Trp466Cys change specifically is limited to its presence in sequencing datasets — no functional studies or large association studies have examined this specific variant.

The Mechanism

LRP8 (ApoER2) contains an N-terminal ligand-binding domain³³ N-terminal ligand-binding domain
Composed of cysteine-rich LDL receptor type A repeats that coordinate calcium ions to create the binding surface for apolipoprotein E-containing lipoproteins including beta-VLDL and HDL comprising multiple LDLa repeats. Tryptophan 466 (in the canonical 870-amino-acid isoform) sits within this domain. In adipocytes — where LRP8 is overexpressed approximately 14-fold relative to whole-body average expression — the receptor is thought to mediate apoE-dependent uptake of triglyceride-rich lipoproteins alongside the more extensively studied LRP1 and VLDL receptor.

In macrophages, ApoER2/LRP8 deficiency has been shown to enhance lipid accumulation and susceptibility to oxidized LDL-induced cell death⁴⁴ ApoER2/LRP8 deficiency has been shown to enhance lipid accumulation and susceptibility to oxidized LDL-induced cell death
Zhou L et al. Apolipoprotein E receptor-2 deficiency enhances macrophage susceptibility to lipid accumulation and cell death to augment atherosclerotic plaque progression and necrosis. Biochimica et Biophysica Acta, 2014. ApoER2 limits PPARγ expression in macrophages and promotes cholesterol efflux via ABCA1, favoring an anti-inflammatory, antiatherogenic macrophage phenotype. A missense variant that disrupts ligand-binding domain integrity could reduce ApoER2-mediated cholesterol efflux, increasing foam cell formation risk.

The Evidence

Direct evidence for rs5181 (Trp466Cys) is limited to its presence in the dbSNP database (build 157) and the Illumina genotyping platform — no functional studies or population association studies have examined this variant specifically.

The broader significance of LRP8 missense variants in fat and lipid metabolism is supported by work on the R952Q variant (rs5174)⁵⁵ R952Q variant (rs5174)
Shen GQ et al. An LRP8 variant is associated with familial and premature coronary artery disease and myocardial infarction. Am J Hum Genet, 2007, which encodes a different missense change in LRP8 and has been associated with premature coronary artery disease and elevated plasma triglycerides in independent cohorts. The R952Q variant acts by increasing p38 MAPK activation in response to oxidized LDL, amplifying macrophage inflammatory signaling.

LRP8 has also been associated with triglyceride levels⁶⁶ LRP8 has also been associated with triglyceride levels
Horne BD et al. Genetic variant R952Q in LRP8 is associated with increased plasma triglyceride levels in patients with early-onset CAD and MI. Lipids in Health and Disease, 2012, further implicating the receptor in lipid homeostasis beyond simple LDL clearance.

ApoER2 deficiency in mice with LDL receptor knockout⁷⁷ ApoER2 deficiency in mice with LDL receptor knockout
Zhou et al. 2014 resulted in accelerated atherosclerosis with more complex lesions, more foam cell necrosis, and defective macrophage Akt signaling — demonstrating that loss of ApoER2 function in the lipid-laden vascular environment has substantive metabolic and structural consequences.

Practical Implications

Given the rarity of this variant and the absence of direct clinical studies, specific dietary or supplement recommendations tied exclusively to the Trp466Cys change would exceed the available evidence. However, if this missense variant reduces LRP8 function in a manner analogous to deficiency models, the most evidence-consistent implication is a potential reduction in ApoER2-mediated apoE-lipid uptake and macrophage cholesterol efflux — biological events that link to elevated cardiovascular and metabolic risk.

Carriers of rare LRP8 missense variants may benefit from monitoring of cardiovascular risk biomarkers, particularly plasma triglycerides and LDL-C, and from dietary strategies that reduce the load on the ApoE-receptor system (limiting dietary saturated fat reduces apoB-containing lipoprotein production that must be cleared via this pathway).

Interactions

LRP8 interacts with the ApoE pathway, making APOE genotype (specifically ε2/ε3/ε4) a likely modifier of LRP8 variant effects. A study examining the LRP8 R952Q variant found additive effects with APOE ε4 genotype on apoE plasma levels and MI risk, suggesting that carrying both a LRP8 missense variant and the APOE ε4 allele could compound the impairment of apoE-directed lipid clearance. Related SNPs in LRP8 include rs5174 (R952Q, the best-studied missense variant), rs2297660 (associated with birth weight and schizophrenia susceptibility), and rs5177 (3' UTR variant associated with cardiovascular outcomes).

Ataxin-2 (ATXN2) encodes an RNA-binding protein best known for its role in spinocerebellar ataxia type 2, a neurodegenerative disorder caused by massive CAG repeat expansions in the gene. But common variants in ATXN2 tell a different story — one that intersects aging biology, RNA metabolism, and the health of the cells that let you see. The rs7137828 variant, sitting in an intron of ATXN2, has been robustly linked to primary open-angle glaucoma (POAG), the most common form of glaucoma and the leading cause of irreversible blindness worldwide.

The landmark 2016 meta-analysis¹¹ The landmark 2016 meta-analysis
Cooke Bailey JN et al. Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. Nat Genet. 2016 analyzed 5,990 glaucoma cases and 40,179 controls across U.S., Australian, European, and Singaporean cohorts. It identified rs7137828[T] as a genome-wide significant risk allele (OR=1.17, p=8.73×10⁻¹⁰), and showed that ATXN2 protein is expressed in retinal ganglion cells and the optic nerve head — the exact tissues that degenerate in glaucoma.

The Mechanism

A 2025 functional study²² A 2025 functional study
Shi Song Rong et al. ATXN2 loss of function results in glaucoma-related features supporting a role for Ataxin-2 in primary open-angle glaucoma pathogenesis. Vision Res. 2025 used CRISPR-edited zebrafish to establish how ATXN2 influences eye health. Fish lacking functional atxn2 developed reduced eye size, fewer retinal ganglion cells, elevated intraocular pressure (IOP), and impaired visual function — reproducing the hallmarks of human glaucoma in a model organism. Complementation assays confirmed that 14 human ATXN2 missense variants associated with POAG have genuine functional effects on the gene, pointing to a loss-of-function mechanism.

At the molecular level, ataxin-2 is a multifunctional RNA-binding protein. It regulates mRNA translation via the PI3K/mTOR pathway³³ mRNA translation via the PI3K/mTOR pathway
Lastres-Becker I et al. Nat Commun. 2016, assembles into stress granules during cellular stress, and modulates protein synthesis in response to nutrient deprivation. In retinal ganglion cells, which must maintain long axons all the way to the brain's lateral geniculate nucleus, this RNA metabolism role may be critical for sustaining cellular health across decades. A variant that subtly impairs ataxin-2 function — or alters its expression in relevant tissues — likely reduces the resilience of these non-regenerating neurons over time.

The Evidence

The glaucoma association for rs7137828 meets the highest standards of genetic evidence. The discovery OR of 1.17 per T allele (95% CI approximately 1.12–1.22) was replicated across multiple independent populations including European-American, Australian, and Singaporean cohorts.

A 2023 Brazilian replication⁴⁴ A 2023 Brazilian replication
Rodrigues TAR et al. Ophthalmic Genet. 2023 confirmed the finding in 506 POAG cases and 501 controls: TT homozygotes faced nearly double the risk compared to CC homozygotes (OR=1.717, 95% CI 1.169–2.535, p=0.006). Even CT heterozygotes showed measurable differences in vertical cup-to-disk ratio (VCDR), a structural biomarker of glaucomatous damage, suggesting a dose-dependent effect on optic nerve morphology.

The variant's placement in the 12q24 chromosomal region is also notable for its connections to broader aging biology. An informed GWAS for exceptional longevity⁵⁵ An informed GWAS for exceptional longevity
Fortney K et al. Genome-Wide Scan Informed by Age-Related Disease Identifies Loci for Exceptional Human Longevity. PLoS Genet. 2015 identified the SH2B3/ATXN2 locus as one of just four loci replicated at FDR < 5% for extreme longevity across centenarian cohorts, and noted that ATXN2's Drosophila ortholog extends lifespan when manipulated. The neighboring SH2B3 gene encodes LNK, a signaling adaptor that modulates cytokine and insulin receptor pathways — underscoring how this chromosomal region sits at the crossroads of immune regulation, metabolic aging, and now ocular health.

Practical Actions

POAG is particularly insidious because it causes painless, slow loss of peripheral vision that most people don't notice until substantial damage has occurred. The T allele adds a modest but real increment of lifetime risk on top of other glaucoma risk factors (age, elevated IOP, thin corneas, family history, African ancestry).

The most actionable implication is earlier and more vigilant eye pressure monitoring. Standard guidelines recommend comprehensive eye exams including IOP measurement every 1–2 years from age 40, but carriers of one or two T alleles — especially if combined with other risk factors — have reason to start earlier (age 35) and to specifically request optic nerve imaging (OCT). Caught early, glaucoma is highly manageable with topical medications or laser therapy; caught late, the vision loss is permanent.

Intraocular pressure is also modifiable: aerobic exercise consistently lowers IOP⁶⁶ aerobic exercise consistently lowers IOP
Passo MS et al. Arch Ophthalmol. 1991, and caffeine consumption acutely raises it. For carriers seeking to reduce modifiable risk, regular aerobic activity and monitoring of coffee intake may offer meaningful benefit.

Interactions

The rs7137828 ATXN2 variant sits within the 12q24 locus alongside rs3184504 in SH2B3, which encodes the LNK signaling adaptor and is the primary variant associated with longevity and cardiovascular protection at this locus. The two genes are distinct but biologically intertwined: SH2B3/LNK regulates hematopoietic and immune signaling, while ATXN2 regulates RNA metabolism and protein synthesis. Both contribute to the pleiotropic disease associations of 12q24 — covering autoimmune, cardiovascular, neurodegenerative, and now ocular conditions. Individuals carrying risk alleles at both rs7137828 (ATXN2, glaucoma) and rs3184504 (SH2B3, cardiovascular/longevity) may warrant particularly comprehensive health monitoring across multiple organ systems, though formal combined-risk studies have not been published.

ATXN2 also intersects with TDP-43 biology: intermediate CAG repeat expansions in ATXN2 (27–33 repeats, not yet disease-causing on their own) increase the risk of ALS by stabilizing TDP-43 aggregates. The common rs7137828 variant does not affect repeat length, but highlights ATXN2's biological proximity to RNA metabolism pathways that span glaucoma, neurodegeneration, and aging.

Interleukin-4 is the master architect of the Th2 immune response. It drives B cells to class-switch from IgM to IgE¹¹ IgE
Immunoglobulin E — the antibody class responsible for allergic reactions; IgE binds mast cells and basophils, which explode with histamine upon allergen encounter, steers naive T cells toward the Th2 fate that underlies atopic disease, and suppresses the Th1 arm of immunity that fights intracellular pathogens. A variant in intron 3 of the IL4 gene — rs2227284, historically designated T+2979G — alters the regulatory machinery controlling IL-4 transcription. The T allele is associated with elevated susceptibility to asthma, allergic rhinitis, and severe bacterial infections; the G allele with relative protection across multiple independent study populations.

The Mechanism

rs2227284 sits within intron 3 of IL4 on chromosome 5q31.1. It does not change the IL-4 protein sequence. Instead, it lies in a region that influences IL-4 transcriptional regulation — a stretch of intronic sequence long suspected to be part of the gene's locus control region, the same genomic neighborhood that contains the IL4 intron 3 variable number tandem repeat (VNTR)²² variable number tandem repeat (VNTR)
A repeated DNA motif (RP1 repeat) whose copy number varies between individuals and has been associated with IL-4 production levels; rs2227284 is in strong linkage disequilibrium with the VNTR haplotype in many populations. The strongest statistical link to phenotype is through IgE regulation: a Polish pediatric cohort³³ Polish pediatric cohort
177 asthmatic children versus 194 controls, examining IL4, IL4R, and IL13 variants found that rs2227284 had the most significant association with total IgE levels of any IL4 variant tested (p=0.00047) — a compelling fingerprint that this intronic position modulates IL-4 transcriptional output rather than protein function.

The directionality across populations is consistent: the T allele (GRCh38 plus-strand reference, but the rarer allele in Europeans at ~29% frequency) associates with elevated atopic disease risk and higher IgE, while the G allele (major in Europeans at ~71%) is associated with lower risk. Ethnically, G allele frequency varies enormously — ~71% in Europeans, ~64% in South Asians, ~40% globally, ~16% in East Asians and ~9% in Africans — which explains why directional effects can differ across study populations.

The Evidence

In a study of 393 Japanese women with rhinoconjunctivitis and 703 controls⁴⁴ 393 Japanese women with rhinoconjunctivitis and 703 controls
Kyushu Okinawa Maternal and Child Health Study cohort, using ISAAC criteria for rhinoconjunctivitis definition, the GG genotype at rs2227284 was significantly inversely associated with rhinoconjunctivitis compared with TT (adjusted OR 0.60, 95% CI 0.37–0.98). The protective effect was confined to never-smokers — an important interaction suggesting that smoking, which independently dysregulates IL-4 signaling, can override the genotype's protective direction.

In 503 Chinese Han children with allergic rhinitis and 393 controls⁵⁵ 503 Chinese Han children with allergic rhinitis and 393 controls
a GWAS-loci validation study examining 16 candidate SNPs in childhood AR, the TG genotype was associated with a 0.65-fold decreased risk of AR compared with TT. A C-G-C haplotype spanning rs2243250–rs2227284–rs2243290 was protective, placing the G allele as part of the low-risk regulatory haplotype.

Among 214 Pakistani patients (108 asthma, 106 allergic rhinitis) versus 120 healthy controls⁶⁶ 214 Pakistani patients (108 asthma, 106 allergic rhinitis) versus 120 healthy controls
cross-sectional study examining three IL4 intronic SNPs, rs2227284 showed significant associations with both asthma (chi-square 22.51, p<0.001) and allergic rhinitis (chi-square 57.6, p<0.001) — the strongest p-values among all three IL4 variants studied. A Chinese pediatric study⁷⁷ Chinese pediatric study
392 asthmatic children and 849 controls examining both IL-2 and IL-4 polymorphisms confirmed that rs2227284 was associated with reduced asthma risk in both heterozygotes (p=0.026) and G-allele homozygotes (p=0.001).

Beyond atopy, the variant's immunological reach extends to infection severity. A study of 57 adult pneumococcal pneumonia patients and 280 controls⁸⁸ study of 57 adult pneumococcal pneumonia patients and 280 controls
focused on host genetics and P-CAP susceptibility and severity found IL4 rs2227284 associated with severe pneumococcal community-acquired pneumonia (OR 2.17, p=0.04), consistent with the T allele's effect on Th2 immune polarization impairing Th1-dependent antibacterial clearance. A 2024 Chinese RA study (n=986) additionally found the G allele protective against rheumatoid arthritis development, adding autoimmune susceptibility to the variant's phenotypic repertoire.

Practical Actions

For TT homozygotes — who carry both T alleles and sit at highest risk — the primary value of knowing this genotype is heightened awareness of atopic disease progression. The T allele's clearest clinical signal is in individuals who are already atopically sensitized: if you have eczema, allergic rhinitis, or food allergy, the elevated IL-4 regulatory output at the rs2227284 locus amplifies your risk of asthma development (the atopic march). Monitoring total IgE and seeking early allergist evaluation are the most direct responses.

The smoking interaction documented in the rhinoconjunctivitis data is clinically significant for TG heterozygotes: the G allele's protective effect was abolished in ever-smokers. This means the partial protection the G allele confers is contingent on avoiding tobacco exposure.

For all T-allele carriers, antihistamines and corticosteroid nasal sprays treat symptoms; allergen immunotherapy addresses the underlying Th2-skewing mechanism by redirecting the immune response toward Th1/Treg tolerance and, in doing so, directly opposes the mechanism this variant amplifies.

Interactions

rs2243250 (C-589T, promoter), rs2070874 (C-33T), and rs2243290 are the other major IL4 SNPs studied alongside rs2227284. They form haplotypes that collectively determine IL-4 expression level; rs2243250 is typically the strongest individual signal in promoter-focused studies. rs2227284 and rs2243250 travel together in the protective C-G haplotype (rs2243250 C + rs2227284 G) documented in East Asian cohorts.

rs7130588 (LRRC32/11q13.5) and rs1805011 (IL4Rα I50V) are pathway partners — LRRC32 controls Treg-mediated TGF-β tolerance, and IL4Rα rs1805011 controls IL-4 receptor signaling downstream of IL-4 binding. Carrying risk alleles at multiple nodes of the IL-4/Th2 axis (IL4 production at rs2227284, receptor sensitivity at rs1805011, and Treg tolerance at rs7130588) may cumulatively define the highest-risk atopic phenotype, though formal compound analyses of this exact combination remain unpublished.

The SNCA gene¹¹ SNCA gene
Alpha-synuclein (SNCA) encodes the protein that aggregates into Lewy bodies — the pathological hallmark of Parkinson's disease and related synucleinopathies harbors multiple independent risk variants, each tagging different biological mechanisms at the same locus. rs2736990 sits within intron 4 of SNCA — a region known for a complex CT-rich haplotype structure that influences alpha-synuclein expression and splicing²² complex CT-rich haplotype structure that influences alpha-synuclein expression and splicing — and was the first intronic SNCA variant to reach genome-wide significance in a large European GWAS.

What distinguishes rs2736990 from the other SNCA risk variants profiled in this database (rs356219 and rs356182) is its position in a different linkage disequilibrium (LD) block. The three variants are not correlated with each other by descent, meaning they carry independent risk information. Carriers of the G allele at rs2736990 face meaningfully elevated Parkinson's disease risk regardless of their genotype at the other SNCA loci, and the G allele associates specifically with earlier disease onset and cognitive vulnerability — the same clinical phenotype seen with rs356219, suggesting a shared downstream mechanism related to alpha-synuclein protein levels.

The Mechanism

rs2736990 is classified as an intronic variant³³ intronic variant
A variant located within a non-coding region of a gene (intron); intronic variants can influence gene expression, splicing efficiency, or RNA stability without changing the protein sequence in intron 4 of SNCA. The precise molecular mechanism by which this variant alters disease risk is not fully established, but the leading hypothesis is that it influences SNCA pre-mRNA splicing or expression levels — consistent with the known biology of the intron 4 region. The intron 4 of SNCA is a hotspot for structural variation and CT-repeat polymorphisms (REP1), and rs2736990 is embedded in this functionally active region.

The net effect, supported by population data, is that G-allele carriers have higher circulating alpha-synuclein levels compared to AA carriers — paralleling the mechanism of rs356219. Elevated alpha-synuclein creates a permissive environment for misfolding, oligomer formation, and progressive dopaminergic neuron death in the substantia nigra. Because the variant is intronic, it does not change the alpha-synuclein protein itself but modulates how much of it is produced or how efficiently the mRNA is processed.

The Evidence

The discovery of rs2736990 as a Parkinson's disease risk variant came from a landmark 2009 European genome-wide association study⁴⁴ a landmark 2009 European genome-wide association study
Simón-Sánchez et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genetics, 2009 that enrolled 1,713 cases and 3,978 controls, with replication in an independent cohort of 3,361 cases and 4,573 controls. The SNCA signal at rs2736990 was one of the two strongest associations identified, with OR 1.23 and p=2.24×10⁻¹⁶ — a highly robust association by GWAS standards.

A Chinese Han case-control study⁵⁵ A Chinese Han case-control study
Association of polymorphism in rs2736990 of the α-synuclein gene with Parkinson's disease in a Chinese population. Neurology India, 2013 (515 PD patients, 450 controls) confirmed the C allele as a PD risk factor (OR 1.26, 95% CI 1.04–1.51; p=0.017) and identified a stronger effect in early-onset patients diagnosed at or before age 50 (OR 1.60, 95% CI 1.13–2.26; p=0.007). This early-onset enrichment is clinically significant — it suggests that among younger PD patients, rs2736990 is playing a more prominent etiological role.

A 2017 meta-analysis⁶⁶ 2017 meta-analysis
Association between SNCA rs2736990 polymorphism and Parkinson's disease: a meta-analysis. Neuroscience Letters, 2017 pooling six studies (2,525 PD cases, 2,165 controls) formally established the risk direction: the C allele (G on plus strand) confers increased risk, with an allele model OR of 1.30. Under the recessive model (CC vs TT+TC), the OR for the homozygous risk genotype was 1.52.

The 2017 Brazilian cohort⁷⁷ 2017 Brazilian cohort
Campelo et al. Variants in SNCA Gene Are Associated with Parkinson's Disease Risk and Cognitive Symptoms in a Brazilian Sample. Frontiers in Aging Neuroscience, 2017 (104 PD patients, 98 controls) provided crucial data linking rs2736990 directly to cognitive outcomes. The CC homozygous genotype was associated with OR 2.65 (95% CI 1.13–6.20) for PD overall, and the C allele was significantly more frequent among PD patients with cognitive impairment (70%) versus controls (52%), yielding OR 2.21 (95% CI 1.26–3.85; p=0.005). The C allele also associated with early-onset PD (OR 1.88, 95% CI 1.07–3.29; p=0.028). Notably, this study found that rs2736990 and rs356219 co-occur in a risk haplotype (OR 2.51 for the combined haplotype), confirming their independent but additive contributions.

The largest systematic assessment comes from a 2018 comprehensive meta-analysis⁸⁸ 2018 comprehensive meta-analysis
A Comprehensive Analysis of the Association Between SNCA Polymorphisms and the Risk of Parkinson's Disease. Frontiers in Molecular Neuroscience, 2018 covering 24,075 cases and 22,877 controls across 36 studies. Among 16 SNCA variants analyzed, rs2736990 was classified as one of eight "most recommended" variants (p<1×10⁻⁵) for genetic risk assessment, with OR 1.22 in the allele model (95% CI 1.13–1.31) and OR 1.30 in both dominant and recessive models. The G allele frequency in unaffected controls was 0.56 globally and 0.62 in East Asian controls, confirming the variant is common — not a rare pathogenic mutation, but a frequent risk-modifying variant.

Practical Actions

The actionable profile for rs2736990 is closely related to that of rs356219, since both variants elevate alpha-synuclein levels and both associate with earlier disease onset and cognitive vulnerability. The key targets are mitochondrial dysfunction, oxidative stress that promotes alpha-synuclein misfolding, and impaired autophagy — the cellular cleanup system that normally clears misfolded protein aggregates.

Ubiquinol CoQ10 addresses the mitochondrial complex I dysfunction⁹⁹ Ubiquinol CoQ10 addresses the mitochondrial complex I dysfunction that alpha-synuclein overload drives, while simultaneously reducing the oxidative environment that promotes further misfolding. Regular caffeinated coffee intake shows consistent neuroprotective associations in PD epidemiology¹⁰¹⁰ Regular caffeinated coffee intake shows consistent neuroprotective associations in PD epidemiology, with caffeine shown to reduce alpha-synuclein oligomer toxicity and restore autophagy-mediated clearance of misfolded protein.

For G-allele carriers who are younger or have a family history of PD, establishing a neurological baseline and monitoring for early prodromal signs (hyposmia, REM sleep behavior disorder, constipation, subtle motor asymmetry) is particularly valuable given this variant's association with earlier onset.

Interactions

rs2736990 is independent of both rs356219 and rs356182 at the SNCA locus — each resides in a different LD block. Carriers of risk alleles at multiple SNCA loci face cumulative risk: the 2017 Brazilian study explicitly showed that a haplotype combining rs356219 G and rs2736990 C alleles carries OR 2.51 for PD — higher than either variant alone. This additive relationship suggests that individuals who carry G alleles at both rs2736990 and rs356219 represent a particularly high-priority group for early monitoring and neuroprotective lifestyle strategies.

The early-onset association of rs2736990 has been replicated independently across Mexican, Chinese, and Brazilian populations, suggesting a consistent biological mechanism tied to the intron 4 region's regulatory function.

Every cell in your body depends on a constant supply of folate to make DNA, synthesize amino acids, and run the methylation cycle. Yet folate cannot cross cell membranes on its own. The reduced folate carrier 1 (RFC1), encoded by the SLC19A1 gene on chromosome 21, is the primary gateway — a high-capacity, bidirectional transporter that ferries 5-methyltetrahydrofolate¹¹ 5-methyltetrahydrofolate
The predominant circulating form of folate; the active form used in the methylation cycle (5-MTHF) and other reduced folates into cells against concentration gradients. The rs2838956 variant lies within an intron of this gene and tags a haplotype block that influences how efficiently RFC1 does its job.

The Mechanism

rs2838956 (chr21:45525110, GRCh38) is an intronic A>G single-nucleotide variant in SLC19A1. Intronic variants are not silent bystanders — they can alter RNA splicing²² RNA splicing
The process that removes introns and joins exons to create messenger RNA; intronic variants can shift splice-site recognition, alter exon inclusion, or change expression levels or transcription factor binding, changing the amount or structure of the RFC1 protein produced. The mechanistic route for rs2838956 has not been directly resolved, but its consistent presence in haplotype blocks associated with altered RFC1 transport activity suggests it is a regulatory tag SNP rather than a purely neutral bystander. The G allele at this position defines the RFC1 haplotype associated with altered methotrexate uptake³³ altered methotrexate uptake
Methotrexate enters cells through the same RFC1 transporter as folate; reduced transport affects both therapeutic drug delivery and cellular folate homeostasis.

RFC1 operates as a secondary active transporter, exchanging intracellular organic anions (principally thiamine pyrophosphate) for extracellular folates. Its preferred substrates are reduced folates — 5-MTHF and 5-formylTHF — while oxidized folic acid has orders-of-magnitude lower affinity⁴⁴ orders-of-magnitude lower affinity for the carrier. This biochemical preference means RFC1 function matters most for how efficiently cells import the active folate forms from circulation, and less for folic acid absorbed directly from gut lumen (which uses separate transporters).

The Evidence

The clearest clinical signal for rs2838956 comes from pharmacogenomics — specifically, how this variant affects methotrexate (MTX) response in rheumatoid arthritis (RA) and childhood leukemia, because MTX enters cells through the same RFC1 transporter as folate.

A UK cohort study of 219 RA patients⁵⁵ UK cohort study of 219 RA patients
Daly AK et al. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J, 2012 found the G allele of rs2838956 associated with MTX treatment failure (OR 1.45, 95% CI 1.00–2.10, p trend = 0.04). G allele carriers showed higher rates of inadequate disease response, suggesting reduced RFC1-mediated MTX uptake into inflamed synovial cells.

A Portuguese RA study⁶⁶ Portuguese RA study
Hider SL et al. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity. Toxicol Sci, 2014 found the complementary pattern for gastrointestinal toxicity: A allele carriers had increased GI adverse effects (OR 3.21, p = 0.049). This apparent paradox — G allele linked to lower efficacy while A allele linked to higher toxicity — suggests the A allele may enhance RFC1 transport activity in some tissues, delivering more MTX to the GI epithelium (causing toxicity) while also enabling better drug delivery to target tissues (improving RA response). The GGAG haplotype incorporating rs2838956 was independently associated with GI toxicity (p = 0.029).

A pediatric ALL study⁷⁷ pediatric ALL study
Organista-Nava J et al. Folate transport gene polymorphisms in Mexican children with ALL. Front Pharmacol, 2016 of 73 cases and 133 controls found remarkably elevated ALL risk in AG heterozygotes (OR = 44.69, 95% CI 10.42–191.63, p = 0.0001). The extraordinarily large odds ratio in an over-dominant model suggests an interaction effect specific to heterozygous status in this admixed Mexican population; replication in larger independent cohorts is needed before this finding can be used clinically.

For the general population without autoimmune disease or chemotherapy exposure, the primary implication is folate transport efficiency — individuals carrying the G allele may have a modestly different RFC1 haplotype that alters how efficiently cells import dietary folates from the bloodstream.

Practical Actions

For most people, the rs2838956 variant has a modest effect that becomes clinically relevant mainly in two contexts: (1) if methotrexate is prescribed for RA or other autoimmune conditions, and (2) if other folate-pathway variants (particularly MTHFR C677T) compound the functional load on the folate transport system. Using 5-MTHF rather than folic acid is especially relevant for RFC1 variant carriers because RFC1 transports reduced folates far more efficiently than oxidized folic acid, meaning the form of folate matters independently of any downstream conversion issues.

Interactions

rs2838956 is most studied in the context of SLC19A1 haplotypes that include rs1051266 (H27R, the most-studied RFC1 coding variant), rs7499, and rs3788200. The haplotype context determines the net functional effect more reliably than any single SNP alone. For folate-pathway burden, rs2838956 compounds with MTHFR C677T (rs1801133) and A1298C (rs1801131) — individuals carrying both MTHFR impairment and an RFC1 transport variant face reduced folate at two steps: import into cells and conversion to the active methylfolate form. This two-step bottleneck scenario warrants more aggressive use of bioactive folate forms (5-MTHF) and monitoring of homocysteine levels. The interaction between MTHFR and SLC19A1 variants has been noted in the literature on one-carbon metabolism but has not been formally quantified in a compound-action study.